

1 **Recapitulation of Cellular Senescence, Inflammation, and Fibrosis in Human Kidney-**  
2 **Derived Tubuloids by Repeated Cisplatin Treatment**

3 Yuki Nakao<sup>1#</sup>, Yutaro Mori<sup>1#\*</sup>, Makiko Mori<sup>1</sup>, Shintaro Mandai<sup>1</sup>, Tamami Fujiki<sup>1</sup>, Hiroaki  
4 Kikuchi<sup>1</sup>, Fumiaki Ando<sup>1</sup>, Koichiro Susa<sup>1</sup>, Takayasu Mori<sup>1</sup>, Yuma Waseda<sup>2</sup>, Soichiro Yoshida<sup>2</sup>,  
5 Yasuhisa Fujii<sup>2</sup>, Eisei Sohara<sup>1</sup>, Shinichi Uchida<sup>1</sup>

6 <sup>1</sup>Department of Nephrology and <sup>2</sup>Department of Urology, Graduate School of Medical and Dental  
7 Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

8 <sup>#</sup>These authors contributed equally to this work.

9

10 Lead contact and Corresponding author:

11 Yutaro Mori, MD, PhD

12 Department of Nephrology

13 Graduate School of Medical and Dental Sciences

14 Tokyo Medical and Dental University

15 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

16 Phone: +81-3-5803-5214; Fax: +81-3-5803-5215; Email: [y-mori.kid@tmd.ac.jp](mailto:y-mori.kid@tmd.ac.jp)

17

18 Runing title:

19 Recapitulation of Cellular Senescence in Human Tubuloids

20

21 **Abstract**

22 In the pursuit of more accurate pathophysiological models for assessing renal drug response, the  
23 development of kidney organoids derived from human pluripotent stem cells represents a  
24 significant step forward. However, recapitulating aging/senescence-associated pathophysiology  
25 within these models remains challenging. Here, we present an innovative approach to generate  
26 more homogeneous epithelial-like structures known as “tubuloid” using primary human renal  
27 proximal tubular epithelial cells (hRPTECs) cultured from human resected kidneys, as a refined  
28 alternative. We evaluated the efficacy of tubuloids using cisplatin treatment at three different  
29 concentrations: 0.2, 2.0, and 20.0  $\mu\text{g}/\text{mL}$ . Tubuloids showed highly differentiated structures with  
30 proximal tubular epithelial cells that expressed lotus tetragonolobus lectin and LRP2/Megalin.  
31 Upon exposure to cisplatin,  $\gamma\text{H2AX}$  expression increased in a dose-dependent manner, indicating  
32 DNA damage. Cisplatin treatment also resulted in the expression of Kidney Injury Molecule-1  
33 (KIM-1) and Cleaved Caspase-3, which are indicators of kidney injury and apoptotic signaling,  
34 respectively. Repeated cisplatin administration resulted in upregulation of the cellular senescence  
35 marker p16, alongside increased secretion of inflammatory cytokines IL-1 $\beta$  and IL-6, indicating  
36 the induction of a senescence-associated secretory phenotype (SASP). Furthermore, supernatant  
37 collected from cisplatin-treated tubuloids induced myofibroblast activation, indicating the onset of  
38 renal fibrosis. We successfully established a tubuloid-based model of cisplatin-induced kidney  
39 injury using hRPTECs. Tubuloids provide a novel platform for studying the response of renal  
40 epithelial cells to toxins and therapeutics. Tubuloids can replicate cellular senescence, SASP, and  
41 fibrosis, making them a promising pathophysiological model for chronic kidney disease (CKD),  
42 providing insights into the disease’s fibrotic mechanisms.

43

44 **Keywords**

45 organoid, tubuloid, cisplatin nephrotoxicity, fibrosis, chronic kidney disease

46

47 **Translational Statement**

48 Recapitulating aging/senescence-associated pathophysiological reaction in kidney organoids

49 remains challenging. Our study reveals that tubuloids could be novel candidate for chronic

50 kidney disease (CKD) model.

## 51 **Introduction**

52 Chronic kidney disease (CKD) is an irreversible, progressive condition characterized by the  
53 gradual sclerosis of glomeruli, accompanied by tubular atrophy, interstitial fibrosis, and infiltration  
54 of inflammatory cells [1]. Despite its significant impact on global health, the underlying  
55 pathogenic mechanisms of CKD are poorly understood, and a definitive cure has yet to be  
56 discovered.

57 In recent years, a shared mechanism for inflammation and fibrosis in CKD has emerged. It  
58 is proposed that the initial trigger is DNA damage in tubular epithelial cells, which initiates a  
59 cascade involving DNA damage response, cell cycle arrest [2], cellular senescence [3, 4], and the  
60 subsequent development of the senescence-associated secretory phenotype (SASP) [5]. To  
61 investigate these processes, various models have been created, including cell and animal models,  
62 as well as kidney organoids derived from human induced pluripotent stem cells (iPSCs) [6] or  
63 human embryonic stem cells (ESCs). These models show promise in understanding the  
64 pathogenesis of CKD and investigating potential therapeutic interventions [7]. Nonetheless, one  
65 critical limitation of existing models is their inability to fully capture the aging process, particularly  
66 the phenomenon of cellular senescence, which manifests prominently in humans with a lifespan  
67 greater than 80 years. Experimental animals such as mice, with a lifespan of only two years, do  
68 not fully replicate the range of age-related diseases associated with cellular senescence found in  
69 humans.

70 Furthermore, despite progress, kidney organoids derived from iPSCs or ESCs have  
71 primarily focused on replicating fetal kidney development stages, falling far short of accurately  
72 mimicking age-related diseases such as CKD.

73           In this context, “tubuloids,” a three-dimensional structure resembling renal tubules, were  
74 first reported in 2019. These tubuloids come from adult primary human renal proximal tubular  
75 epithelial cells (hRPTECs) [8]. Schutgens et al. pioneered the culture of primary hRPTECs derived  
76 from adult human kidneys and urine, successfully producing tubuloids capable of replicating viral  
77 infections in proximal tubules and hereditary diseases [9]. Building on this work, we have further  
78 refined the tubuloid generation protocol with human resected kidneys [10]. Our research has  
79 focused on understanding the response of tubuloids to a nephrotoxicant and a potential therapeutic  
80 agent. Despite these advances, developing a comprehensive pathophysiological model for aging  
81 or senescence-associated diseases using tubuloids remains a promising area of research.

82           Cisplatin, a commonly used therapeutic agent for various malignancies, including lung  
83 cancer, has a well-known side effect known as cisplatin-induced nephropathy [11, 12]. This  
84 condition is defined by the induction of DNA damage in the renal proximal tubules [13]. The  
85 cellular response to this damage includes cell cycle arrest during the repair phase following  
86 cisplatin-induced injury, which eventually leads to cellular senescence and SASP. These processes  
87 are thought to be the final detrimental mechanisms that underpin the progression from acute kidney  
88 injury (AKI) to CKD [14, 15]. Thus, modeling cisplatin-induced nephropathy is not only useful  
89 for studying nephrotoxicity but also has the potential to mimic the progression of CKD.

90           The primary goal of this study was to assess the disease-modeling potential of tubuloids  
91 by exposing them to cisplatin to reproduce cisplatin-induced nephropathy. Furthermore, we  
92 wanted to investigate whether tubuloids could replicate cellular senescence and its associated  
93 responses beyond the immediate effects of cisplatin nephrotoxicity to simulate the transition from  
94 AKI to CKD, or even model CKD itself.

95

96 **Methods**

97 **Cell culture experiment:** Human kidney samples were collected from patients undergoing  
98 clinically indicated nephrectomy at the Tokyo Medical and Dental University Hospital in Tokyo,  
99 Japan. The protocol was approved by the Institutional Review Board of the Ethics Committee of  
100 Tokyo Medical and Dental University (M2022-005). Human renal proximal tubular epithelial cells  
101 (hRPTECs) were isolated from unaffected areas of kidneys removed during nephrectomy  
102 procedures performed on patients with renal cell carcinoma or urinary tract malignancies by  
103 modifying a previously established protocol[37]. Briefly, the isolation procedure involved mincing  
104 the human renal cortex and then digesting it in a solution of Collagenase type II (1.0 mg/mL)  
105 (Worthington Biochemical, NJ, USA). The enzyme reaction was terminated with fetal bovine  
106 serum (FBS), and the samples were resuspended in hRPTECs culture medium containing  
107 DMEM/F-12 (Nacalai Tesque, Kyoto, Japan), with BSA (Nacalai Tesque), Antibiotic–  
108 Antimycotic (ThermoFisher Scientific, MA, USA), hydrocortisone (ThermoFisher Scientific, MA,  
109 USA), ITS liquid media supplement (Sigma-Aldrich, MO, USA), and human recombinant  
110 epidermal growth factor (EGF) (ThermoFisher Scientific, MA, USA). The epithelial cells were  
111 cultured for 7-10 days before being used in experiments.

112 To make mouse primary kidney fibroblasts (MPKFs), a 12-week old male C57BL/6J  
113 mouse was sacrificed. MPKFs were isolated by mincing the mouse kidneys and digesting them in  
114 a solution of Collagenase type II (1.0 mg/mL). The enzyme reaction was stopped with FBS, and  
115 the samples were resuspended in DMEM with 10% FBS, 5 ng/ml FGF-basic (ThermoFisher  
116 Scientific), and Antibiotic-Antimycotic. The MPKFs were used after 3 to 5 passages. All cells  
117 were maintained in a CO<sub>2</sub> incubator (5% CO<sub>2</sub>) at 37°C to ensure optimal growth conditions. All  
118 animal studies were performed in accordance with the guidelines for animal research of Tokyo

119 Medical and Dental University. The study protocol was approved by the Animal Care and Use  
120 Committee of Tokyo Medical and Dental University (approval no. A2023-109C).

121  
122 **Human Renal Tubuloids Culture:** hRPTECs were seeded onto ultralow attachment plates at a  
123 density of  $5.0 \times 10^5$  cells/well using Advanced RPMI 1640 medium (ThermoFisher Scientific),  
124 supplemented with 5% FBS. After a 2-day incubation period, Matrigel (Corning, NY, USA) was  
125 added to stimulate tubuloid formation. The following day, the culture medium was changed to  
126 Advanced RPMI 1640 medium with 5% FBS, EGF, FGF2, and HGF (tubuloids media). Media  
127 was changed once or twice weekly to maintain optimal cell growth conditions. Tubuloids were  
128 usually ready for experimentation within 1–2 weeks of starting the culture.

129  
130 **Fibrosis bioassay.** The tubuloids were treated with or without cisplatin on a repeated basis.  
131 Following a 48-hour exposure period, the media was replaced with serum-free DMEM to facilitate  
132 conditioning. After an additional 48 hours of incubation, the culture supernatants were collected  
133 as conditioned media.

134 MPKFs were uniformly plated at a density of  $2.0 \times 10^4$  cells/well in an 8-well chamber  
135 slide (Nunc Lab-Tek Chamber Slide system) (ThermoFisher Scientific) with 10% FBS-DMEM.  
136 The next day, the conditioned media harvested from the tubuloids was added to MPKFs and  
137 incubated for 48 hours. The MPKFs on the 8-well chamber slide were then washed twice with PBS  
138 and immunostained as described below.

139  
140 **Immunofluorescence staining.** The tubuloids were fixed with 4% paraformaldehyde (PFA) in  
141 PBS and permeabilized with 0.1% Triton X-100 in PBS. The tubuloids were then blocked with

142 3% BSA in PBS and incubated with primary antibodies for 1 hour. Tubuloids were washed  
143 thoroughly with PBS and then incubated with secondary antibodies for 30 minutes. After another  
144 round of PBS washing, the tubuloids were placed on glass slides. The slides were mounted with  
145 Prolong Glass Antifade Mountant with NucBlue Stain (ThermoFisher Scientific) and cover-  
146 slipped for fluorescence microscopy.

147 The following primary antibodies were used: rabbit anti-LRP2 / Megalin antibody (1:100)  
148 (ab236244, Abcam, MA, USA), rabbit anti- $\gamma$ H2AX antibody (1:200) (#9718, Cell Signaling  
149 Technology, MA, USA), mouse anti- $\text{Na}^+/\text{K}^+$ -ATPase antibody (1:200) (05-369, Sigma-Aldrich),  
150 mouse anti-KIM-1 antibody (1:200) (AF1750, R&D systems, MN, USA), rabbit anti-caspase-3  
151 antibody (1:200) (#9664, Cell Signaling Technology), rabbit anti-Vimentin antibody (1:200)  
152 (10366-1-AP, Proteintech, IL, USA), rabbit anti-p16-INK4A polyclonal antibody (1:200) (10883-  
153 1-AP, Proteintech), rabbit anti-IL-1 $\beta$  polyclonal antibody (1:200) (bs-0812R, Bioss, MA, USA)  
154 and rabbit anti- $\alpha$ SMA antibody conjugated with Cy3 (1:400) (C6198, Sigma-Aldrich) were used.  
155 To stain the brush border of the proximal tubular epithelium, LTL, Biotinylated (B-1325-2, Vector  
156 Laboratories, CA, USA) was used instead of primary antibodies (1:200). Streptavidin, Alexa Fluor  
157 633 conjugate (S21375, ThermoFisher Scientific) was then applied (1:500).

158 For the immunofluorescence staining of fibrosis bioassay, MPKFs plated on an 8-well  
159 chamber slide were washed before being fixed with 4% PFA-PBS. The cells were permeabilized  
160 with 0.1% Triton X-100 in PBS and then blocked with 3% BSA.

161 All images were captured using either standard or confocal microscopy (Eclipse Ti2 from  
162 Nikon), with the NIS-Elements Advanced Research microscope system serving as the operating  
163 system. Quantification of stained area was done using ImageJ Fiji  
164 (<https://imagej.net/software/fiji/downloads>).



165

166 **Quantitative reverse transcription-polymerase chain reaction (qRT-PCR):** The qRT-PCR  
167 analysis of human IL-1 $\beta$ , IL-6, and 18S mRNA followed established protocols. The real-time PCR  
168 detection system utilized was the Thermal Cycler Dice Real Time System Lite TP700 (Takara Bio,  
169 Shiga, Japan) along with TB green Premix Ex Taq II (Takara Bio, Shiga, Japan) [38]. The total  
170 RNA was extracted from frozen kidney tubuloids stored at  $-80^{\circ}\text{C}$  using Sepasol-RNAI Super G  
171 (Nacalai Tesque, Kyoto, Japan). cDNA was then synthesized from the isolated total RNA using  
172 ReverTra Ace (TOYOBO, Tokyo, Japan) [39]. The generated cDNA was then amplified through  
173 40 PCR cycles, with denaturation at  $95^{\circ}\text{C}$  for 5 seconds and annealing/extension at  $60^{\circ}\text{C}$  for 30  
174 seconds.

175 The nucleotide sequences of the primers utilized for qRT-PCR analysis are as follows.

176 human 18S.

177 Forward: 5'-GCAGAATCCACGCCAGTACAAG-3'

178 Reverse: 5'-GCTTGTTGTCCAGACCATTGGC-3'

179 human IL-1 $\beta$ .

180 Forward: 5'- CCACAGACCTTCCAGGAGAATG -3'

181 Reverse: 5'- GTGCAGTTCAGTGATCGTACAGG -3'

182 human IL-6.

183 Forward 5'- AGACAGCCACTCACCTCTTCAG -3'

184 Reverse: 5'- TTCTGCCAGTGCCTCTTTGCTG -3'

185

186 **Western blot analysis.** The tubuloids were lysed, and the protein was purified. Protein bands were  
187 visualized using Western Blue (Promega, WI, USA). Rabbit anti-ERK2 (p44/42 MAPK) antibody

188 (9102S, Cell Signaling Technology) (1:200) was used as a loading control. Primary antibodies  
189 were also used, such as rabbit anti-p16-INK4A polyclonal antibody (1:200) (Proteintech), mouse  
190 anti-KIM-1 antibody (1:200) (R&D systems), rabbit anti-caspase-3 antibody (1:200) (Cell  
191 Signaling Technology), and rabbit anti-Vimentin antibody (1:200) (Proteintech). Densitometry  
192 was performed by using Image J Fiji (<https://imagej.net/software/fiji/downloads>).

193  
194 **Quantification and Statistical Analysis** Figure Legends specify the number of samples assayed  
195 in each experiment. To determine significant differences between groups, a one-way analysis of  
196 variance was used. A p-value of less than 0.05 was considered statistically significant. All  
197 statistical analyses were performed with GraphPad Prism by GraphPad Software Inc. (San Diego,  
198 CA, USA).

199

## 200 **Results**

### 201 **Primary human renal proximal tubular epithelial cells (hRPTECs) form highly polarized** 202 **structure**

203 To form tubuloids, human renal proximal tubular epithelial cells (hRPTECs) were isolated from  
204 the cortex of human kidneys, embedded in a basement membrane gel, and cultured with various  
205 growth factors (**Figure 1A**). Using precise techniques that included finely mincing the cortex  
206 portion of the human kidneys and selective culturing of epithelial cells in a serum-free medium  
207 supplemented with epidermal growth factor (EGF), primary cultured cells, primarily proximal  
208 tubular epithelial cells, were successfully established (**Figure 1B and 1C**).

209 Tubuloids were then formed over approximately a two-week protocol (**Figure 1D**).  
210 Specifically, hRPTECs were seeded on an ultralow attachment plate (**Figure 1E**), followed by the  
211 addition of Matrigel and media containing fetal bovine serum, EGF, fibroblast growth factor 2  
212 (FGF2), and hepatocyte growth factor (HGF). Multiple tubuloids were formed in a single well,  
213 with nearly uniform sizes. The epithelial cells formed tubular-like structures that encircled the  
214 basement membrane gel (**Figure 1F**). The three-dimensional architecture was confirmed by  
215 manipulating the microscope along the Z-axis direction (**Figure 1G**). Notably, the cells formed a  
216 monolayer structure similar to tubules or renal cysts, rather than a spheroid-like structure.  
217 Furthermore, tubuloids expressed differentiation markers associated with proximal tubular  
218 epithelial cells, such as lotus tetragonolobus lectin (LTL) and LDL Receptor Related Protein 2  
219 (LRP2/Megalin), confirming their highly differentiated and polarized structure (**Figure 1H**)[16].

220

### 221 **Cisplatin Exposure Induces Tubular Structure Collapse and Elicits Acute DNA Damage** 222 **Response (DDR) in Tubuloids**

223 To test the sensitivity of tubuloids against a nephrotoxicant, we exposed them to cisplatin.  
224 Cisplatin causes cytotoxicity by entering proximal tubular epithelial cells primarily through  
225 Organic Cation Transporter 2 (OCT2) [17], resulting in direct DNA damage (**Figure 2A**).  
226 Consistent with previous reports highlighting the activation of DNA damage response (DDR)  
227 pathways, we found significant upregulation of  $\gamma$ H2AX, a marker of DNA double-strand breaks,  
228 in both *in vivo* and *in vitro* [18]. Initially, tubuloids were treated with cisplatin at three  
229 concentrations of 0.2, 2.0, and 20.0  $\mu$ g/mL to determine dose-dependent responses. Notably, high-  
230 dose cisplatin treatment collapsed the three-dimensional tubuloid architecture, (**Figure 2B**),  
231 demonstrating the extent of DNA damage caused by cisplatin exposure (**Figure 2C**). Furthermore,  
232 immunostaining analyses revealed a significant reduction in the expression levels of differentiation  
233 markers such as LRP2 and Na<sup>+</sup>/K<sup>+</sup>-ATPase after cisplatin treatment. This downregulation  
234 indicates a concomitant process of cellular dedifferentiation, possibly as an adaptive response to  
235 cytotoxic insult (**Figures 2D and 2E**).

236 Additionally, there was an increase in the expression of a renal injury marker, Kidney  
237 Injury Molecule-1 (KIM-1) [19], and an apoptosis marker, Cleaved Caspase-3 (**Figure 2F, G, and**  
238 **H**), which was consistent with previous findings [20]. These findings further support the sensitivity  
239 of tubuloids to cisplatin-induced injury and validate their use as a model system for studying acute  
240 responses, including DDR.

241 Interestingly, we found that high concentrations of cisplatin increased the expression of  
242 Vimentin, an intermediate filament specific to mesenchymal cells (**Figure 2I and J**). This suggests  
243 that proximal tubular epithelial cells may undergo epithelial-mesenchymal transition (EMT) as  
244 part of a tissue repair mechanism [21, 22]. The activation of Vimentin following DDR has been

245 reported previously [23], and our study confirms this sequential response in cisplatin-treated  
246 tubuloids, elucidating the molecular dynamics underlying cisplatin-induced nephrotoxicity.

247

### 248 **Tubuloids show cellular senescence and release inflammatory cytokines following repeated** 249 **cisplatin treatment**

250 To assess the potential for replicating chronic responses, tubuloids were subjected to prolonged  
251 treatment of cisplatin. Initially, cisplatin was administered at concentrations of 0.2 and 2.0  $\mu\text{g}/\text{mL}$ .  
252 The media was then replaced three times to reduce residual cisplatin, and standard culture  
253 conditions were applied for one day, completing one cycle. This was considered one cycle, and  
254 the next day, cisplatin was given again at similar concentrations (**Figure 3A**). The cycle was  
255 repeated five times. Although treatment with 20.0  $\mu\text{g}/\text{mL}$  cisplatin caused significant disruption  
256 of tubuloids and cell death (**Figure 2**), this concentration was excluded from the experimental  
257 setup to focus on long-term chronic responses.

258 In the repeated cisplatin administration model, we observed the expression of p16, which  
259 is well-established (**Figure 3B, C, and D**) and consistent with previous findings [24]. Additionally,  
260 we confirmed an increased expression of the inflammatory cytokine IL-1 $\beta$  at a concentration of  
261 2.0  $\mu\text{g}/\text{mL}$  through immunofluorescence analyses (**Figure 3E**). Quantitative PCR analysis  
262 revealed a significant upregulation in mRNA levels of both IL-1 $\beta$  and IL-6, ranging from 50 to  
263 100-fold compared to controls, in the group subjected to repeated administration of 2.0  $\mu\text{g}/\text{mL}$   
264 cisplatin ( $P = 0.0167$ ; IL-1 $\beta$  and  $P = 0.011$ ; IL-6) (**Figure 3F and G**). These findings reveal that  
265 repetitive DNA damage induced by cisplatin caused cellular senescence, which resulted in the  
266 acquisition of an SASP.

267

268 **Secretions released from cisplatin-treated tubuloids strongly promote myofibroblast**  
269 **differentiation *in vitro***

270 We hypothesized that prolonged exposure of tubuloids to high concentrations of cisplatin would  
271 promote myofibroblast activation, potentially contributing to tissue fibrosis via the secretion of  
272 paracrine factors from tubuloids, as previously reported *in vivo* [25]. To test this hypothesis, we  
273 used a fibrosis bioassay, as described previously [10] (**Figure 4A**). Initially, tubuloids were  
274 divided into three groups: one receiving no cisplatin, one receiving 0.2 µg/mL cisplatin, and  
275 another receiving 2.0 µg/mL cisplatin. Each group received repeated treatments. Following  
276 cisplatin administrations, the medium was changed three times to remove residual cisplatin, and  
277 the tubuloids were cultured for an additional 2 days in serum-free conditions to produce  
278 conditioned media (CM) containing secreted paracrine factors. Subsequently, the collected CM  
279 was administered to fibroblasts derived from the mouse renal cortex (**Figure 4B**). The activation  
280 of myofibroblasts was assessed by evaluating the expression of  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA)  
281 [26].

282 CM obtained from tubuloids repeatedly treated with 2.0 µg/mL cisplatin showed the most  
283 significant promotion of fibrosis ( $P = 0.0001$ ) (**Figure 4C and D**). This concentration of cisplatin,  
284 as shown in **Figure 3**, corresponds to the maximal secretion levels of IL-1 $\beta$  and IL-6 from  
285 tubuloids, indicating consistency. Furthermore, direct administration of cisplatin to mouse  
286 fibroblasts did not result in myofibroblast activation, decisively ruling out cisplatin as a direct  
287 fibrosis inducer on fibroblasts. The fibrosis bioassay confirmed that various paracrine factors  
288 secreted from tubuloids during repeated treatment of cisplatin have a fibrogenic effect on tissues.  
289

## 290 **Discussion**

291 Our findings provide compelling evidence of the negative effects of cisplatin on tubuloids,  
292 elucidating the cascade of events initiated by DNA damage induction. The dose-dependent  
293 increase in  $\gamma$ H2AX expression is a reliable indicator of DNA damage, supporting previous findings.  
294 Upon DNA damage, tubuloids exhibit a sensitive acute phase response as evidenced by increased  
295 expression of the kidney injury marker KIM-1 and the apoptosis marker Cleaved Caspase-3, which  
296 is consistent with DDR activation. There was also an increase in Vimentin expression, which  
297 indicates epithelial-mesenchymal transition (EMT).

298 The well-preserved three-dimensional structure of tubuloids collapsed upon exposure to  
299 cisplatin, accompanied by a process of dedifferentiation marked by reduced expression levels of  
300  $\text{Na}^+/\text{K}^+$ -ATPase and LRP2/Megalin. Furthermore, repeated long-term administration of cisplatin-  
301 increased the expression of the cellular senescence marker, p16. Tubuloids developed a  
302 senescence-associated secretory phenotype (SASP), releasing inflammatory cytokines like IL-1 $\beta$   
303 and IL-6, causing a chronic inflammatory response in surrounding tissues. These secretions from  
304 tubuloids significantly increased fibrosis in the surrounding interstitial area, as confirmed by the  
305 fibrosis bioassay.

306 CKD research is difficult due to the complexity of the underlying conditions. A significant  
307 impediment to research into CKD is the lack of a reliable disease model. CKD is inextricably  
308 linked to aging and senescence, making it particularly difficult to model in experimental settings.  
309 Currently, the primary models for studying CKD are mice, which, despite their utility, live only  
310 about two years. This timeframe does not adequately represent the decades-long progression of  
311 chronic diseases such as CKD in humans. Furthermore, mouse models are a highly homogeneous  
312 population, lacking the diversity observed in human CKD cases. Given the variability in CKD

313 progression among humans, which is influenced by factors such as gender, race, age, and  
314 environmental exposures, mouse models fail to capture the complexities of human CKD  
315 adequately. This discrepancy reveals a significant gap in our current understanding, emphasizing  
316 the need for more robust and clinically relevant models to advance CKD research.

317         In recent years, kidney organoids derived from induced pluripotent stem cells (iPSCs) or  
318 embryonic stem cells (ESCs) have emerged as promising disease models for the study of kidney  
319 diseases [27-29]. However, current technologies primarily produce organoids that look like fetal  
320 kidneys, making it difficult to replicate age-related features associated with CKD in older people  
321 [30]. Furthermore, iPSC-derived kidney organoids require complex differentiation induction  
322 procedures and skilled techniques, complicating their application. Primary cultured cells derived  
323 from resected human kidneys and kept in two-dimensional conditions fail to fully replicate the  
324 cellular polarity and three-dimensional structures found in living tissues. As a result, while these  
325 models provide valuable insights, they have limitations that prevent them from accurately  
326 representing the complexity of CKD pathogenesis and progression.

327         Conventional disease models for CKD, such as mouse models, iPSC/ESC kidney  
328 organoids, and two-dimensional primary cultured cells from human kidneys, struggle to fully  
329 replicate aging, senescence, and ease of production. However, the human kidney-derived tubuloids  
330 developed in our study provide significant improvements over traditional pathological models for  
331 CKD. Tubuloids are formed by cells obtained from patients that reflect their age and may exhibit  
332 senescence, as evidenced by the control condition without cisplatin treatment (**Figure 3B, C, and**  
333 **D**). This unique feature addresses the limitation of other models by incorporating the aging process  
334 directly into the system.



335           The formation of tubuloids follows a remarkably simple protocol, requiring no specialized  
336 techniques. Culture is carried out in standard 24-well ultra-low attachment plates, and as shown  
337 in **Figure 1F**, multiple tubuloids develop within each well. During sample collection for western  
338 blotting, qPCR, and immunofluorescence, we harvested one sample per well as an independent  
339 condition, resulting in multiple tubuloids in each sample, effectively reducing variability across  
340 individual tubuloids.

341           Expanding our study to include tubuloids from multiple patients shows promise for  
342 capturing individual differences in kidney responses to various stimuli. Notably, our tubuloid  
343 production protocol allows us to derive these structures from different patients simultaneously,  
344 under uniform conditions (manuscript in preparation). These characteristics point to tubuloids'  
345 potential as a novel and useful screening tool for renal toxicity in drug discovery efforts.

346           Tubuloids have a highly differentiated three-dimensional structure[31] and mimic  
347 physiological responses to nephrotoxicants[32, 33]. Previous research has shown that these well-  
348 differentiated tubuloids express a diverse set of channels and transporters, providing them with  
349 greater physiological functionality than cells cultured in two dimensions [34]. This increased  
350 physiological fidelity is likely to explain the observed sensitivity to cisplatin in our study,  
351 facilitating the replication of cellular senescence and other key responses. Importantly, tubuloids  
352 may capture biological reactions that are difficult to detect in conventional two-dimensional cell  
353 cultures.

354           The primary focus of this study was cisplatin-induced nephropathy. However, our  
355 overarching goal goes beyond this single study to develop a strong pathophysiological model for  
356 CKD using human kidney-derived tubuloids. The precise mechanisms underlying CKD following  
357 cisplatin chemotherapy remain largely unknown. However, even low-dose cisplatin has been

358 shown to cause long-term renal pathologies similar to CKD [35]. Cisplatin-induced nephropathy  
359 is caused by the uptake of cisplatin into proximal tubular epithelial cells via OCT2, resulting in  
360 direct damage to nuclear DNA. This DNA damage initiates a cascade of DNA damage response  
361 (DDR) processes: some cells die via programmed cell death, such as apoptosis, while others  
362 activate the cell cycle in an attempt to compensate for the loss of damaged cells. When DNA  
363 damage reaches a critical threshold, it causes cell cycle arrest, particularly in the G2/M phase[2],  
364 preventing further division, a sign of cellular senescence.

365         Senescent cells have been shown to activate the SASP, resulting in the secretion of a variety  
366 of inflammatory and fibrotic cytokines. This cascade causes inflammation and fibrosis in the  
367 surrounding tissue while remaining resistant to cell death. This mechanism, which is driven by  
368 cellular senescence and SASP induced by DNA damage, is a significant contributor to renal  
369 fibrosis. It is an important part of the transition from AKI to CKD, as well as the broader  
370 pathophysiology of CKD, which goes beyond cisplatin-induced nephropathy.

371         In our tubuloid model, we found not only a highly differentiated three-dimensional  
372 structure, but also pathophysiological responses to cisplatin, such as DDR, structural collapse,  
373 dedifferentiation, cell death, epithelial-mesenchymal transition (EMT), cellular senescence, SASP  
374 activation, and fibrotic changes. Our findings suggest that tubuloids have the potential to serve as  
375 a precise disease model for cisplatin-induced nephropathy, faithfully replicating the majority of  
376 pathological mechanisms. This underscores their commitment to developing a comprehensive  
377 CKD model.

378         Moving forward, we plan to improve the sophistication of our disease models by  
379 incorporating coculture systems and microfluidic technologies. Specifically, we intend to  
380 coculture tubuloids with other relevant cell types, including vascular endothelial cells and

381 fibroblasts. Additionally, we plan to simulate physiological urine flow using microfluidic devices  
382 to better mimic the *in vivo* renal microenvironment [36].

383         The successful development of a highly precise disease model for cisplatin-induced  
384 nephropathy using human kidney-derived tubuloids represents a significant advance in kidney  
385 disease research. Using tubuloids as a reliable kidney disease model has great potential for  
386 improving our understanding of various kidney diseases. With their ability to faithfully replicate  
387 cellular senescence, SASP, and fibrosis, tubuloids appear to be a promising tool for modeling CKD,  
388 a condition defined by fibrosis as a final common pathological pathway.

389         In conclusion, our development of tubuloids as a precise disease model for cisplatin-  
390 induced nephropathy is a significant step forward in kidney disease research. Through continued  
391 refinement and innovation, we anticipate that tubuloids will play an important role in advancing  
392 our understanding of CKD and developing novel therapeutic strategies

393

#### 394 **Disclosure Statement**

395 The authors declare that they have no conflicts of interest.

396

397 **References**

- 398 1. Humphreys, B.D., *Mechanisms of renal fibrosis*. Annu Rev Physiol, 2018. **80**: p. 309-326.
- 399 2. Yang, L., et al., *Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury*.  
400 Nat Med, 2010. **16**(5): p. 535-543.
- 401 3. Sturmlechner, I., et al., *Cellular senescence in renal ageing and disease*. Nat Rev Nephrol,  
402 2017. **13**(2): p. 77-89.
- 403 4. Docherty, M.H., et al., *Cellular senescence in the kidney*. J Am Soc Nephrol, 2019. **30**(5):  
404 p. 726-736.
- 405 5. Mylonas, K.J., et al., *Cellular senescence inhibits renal regeneration after injury in mice,*  
406 *with senolytic treatment promoting repair*. Sci Transl Med, 2021. **13**(594).
- 407 6. Takasato, M., et al., *Kidney organoids from human iPS cells contain multiple lineages and*  
408 *model human nephrogenesis*. Nature, 2015. **526**(7574): p. 564-568.
- 409 7. Liu, M., et al., *Studying kidney diseases using organoid models*. Front Cell Dev Biol, 2022.  
410 **10**: p. 845401.
- 411 8. Schutgens, F., et al., *Tubuloids derived from human adult kidney and urine for personalized*  
412 *disease modeling*. Nat Biotechnol, 2019. **37**(3): p. 303-313.
- 413 9. Xu, Y., et al., *Adult human kidney organoids originate from CD24+ cells and represent an*  
414 *advanced model for adult polycystic kidney disease*. Nat Genet, 2022. **54**(11): p. 1690-  
415 1701.
- 416 10. Mori, Y., et al., *KIM-1 mediates fatty acid uptake by renal tubular cells to promote*  
417 *progressive diabetic kidney disease*. Cell Metab, 2021. **33**(5): p. 1042-1061.e7.
- 418 11. Latcha, S., et al., *Long-term renal outcomes after cisplatin treatment*. Clin J Am Soc  
419 Nephrol, 2016. **11**(7): p. 1173-1179.

- 420 12. McSweeney, K.R., et al., *Mechanisms of cisplatin-induced acute kidney injury:*  
421 *pathological mechanisms, pharmacological interventions, and genetic mitigations.*  
422 *Cancers (Basel)*, 2021. **13**(7).
- 423 13. Miller, R.P., et al., *Mechanisms of cisplatin nephrotoxicity.* *Toxins (Basel)*, 2010. **2**(11): p.  
424 2490-2518.
- 425 14. Sato, Y., M. Takahashi, and M. Yanagita, *Pathophysiology of AKI to CKD progression.*  
426 *Semin Nephrol*, 2020. **40**(2): p. 206-215.
- 427 15. Ferenbach, D.A. and J.V. Bonventre, *Mechanisms of maladaptive repair after AKI leading*  
428 *to accelerated kidney ageing and CKD.* *Nat Rev Nephrol*, 2015. **11**(5): p. 264-276.
- 429 16. Nielsen, R., E.I. Christensen, and H. Birn, *Megalin and cubilin in proximal tubule protein*  
430 *reabsorption: from experimental models to human disease.* *Kidney Int*, 2016. **89**(1): p. 58-  
431 67.
- 432 17. Mody, H., et al., *Pharmacodynamic modeling to evaluate the impact of cimetidine, an*  
433 *OCT2 inhibitor, on the anticancer effects of cisplatin.* *Cells*, 2022. **12**(1).
- 434 18. Kuo, L.J. and L.X. Yang, *Gamma-H2AX - a novel biomarker for DNA double-strand*  
435 *breaks.* *In Vivo*, 2008. **22**(3): p. 305-309.
- 436 19. Han, W.K., et al., *Kidney injury Molecule-1 (KIM-1): a novel biomarker for human renal*  
437 *proximal tubule injury.* *Kidney Int*, 2002. **62**(1): p. 237-244.
- 438 20. Tang, C., et al., *Cisplatin nephrotoxicity: new insights and therapeutic implications.* *Nat*  
439 *Rev Nephrol*, 2023. **19**(1): p. 53-72.
- 440 21. Lovisa, S., et al., *Epithelial-to-mesenchymal transition induces cell cycle arrest and*  
441 *parenchymal damage in renal fibrosis.* *Nat Med*, 2015. **21**(9): p. 998-1009.

- 442 22. Grande, M.T., et al., *Snail1-induced partial epithelial-to-mesenchymal transition drives*  
443 *renal fibrosis in mice and can be targeted to reverse established disease*. Nat Med, 2015.  
444 **21**(9): p. 989-997.
- 445 23. Patteson, A.E., et al., *Vimentin protects cells against nuclear rupture and DNA damage*  
446 *during migration*. J Cell Biol, 2019. **218**(12): p. 4079-4092.
- 447 24. Li, S., et al., *Tubular cell senescence promotes maladaptive kidney repair and chronic*  
448 *kidney disease after cisplatin nephrotoxicity*. JCI Insight, 2023. **8**(8).
- 449 25. Liu, B.C., et al., *Renal tubule injury: a driving force toward chronic kidney disease*. Kidney  
450 Int, 2018. **93**(3): p. 568-579.
- 451 26. LeBleu, V.S., et al., *Origin and function of myofibroblasts in kidney fibrosis*. Nat Med,  
452 2013. **19**(8): p. 1047-1053.
- 453 27. Gupta, N., et al., *Modeling injury and repair in kidney organoids reveals that homologous*  
454 *recombination governs tubular intrinsic repair*. Sci Transl Med, 2022. **14**(634): p.  
455 eabj4772.
- 456 28. Hiratsuka, K., et al., *Organoid-on-a-chip model of human ARPKD reveals mechanosensing*  
457 *pathomechanisms for drug discovery*. Sci Adv, 2022. **8**(38): p. eabq0866.
- 458 29. Tabibzadeh, N., et al., *Navigating the kidney organoid: insights into assessment and*  
459 *enhancement of nephron function*. Am J Physiol Renal Physiol, 2023. **325**(6): p. F695-  
460 F706.
- 461 30. Yousef Yengej, F.A., et al., *Kidney organoids and tubuloids*. Cells, 2020. **9**(6).
- 462 31. Yousef Yengej, F.A., et al., *Tubuloid differentiation to model the human distal nephron*  
463 *and collecting duct in health and disease*. Cell Rep, 2024. **43**(1): p. 113614.

- 464 32. Wiraja, C., et al., *Nephrotoxicity assessment with human kidney tubuloids using spherical*  
465 *nucleic acid-based mRNA nanoflares*. Nano Lett, 2021. **21**(13): p. 5850-5858.
- 466 33. Vidal Yucha, S.E. et al., *3D, human renal proximal tubule (RPTEC-TERT1) organoids*  
467 *'tubuloids' for translatable evaluation of nephrotoxins in high-throughput*. PLOS ONE,  
468 2022. 17(11): e0277937.
- 469 34. Yousef Yengej, F.A., et al., *Tubuloid differentiation to model the human distal nephron*  
470 *and collecting duct in health and disease*. Cell Rep, 2024. **43**(1): p. 113614.
- 471 35. Fu, Y., et al., *Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys*  
472 *and renal tubular cells*. Am J Physiol Renal Physiol, 2019. **317**(6): p. F1582-F1592.
- 473 36. Gijzen, L., et al., *Culture and analysis of kidney tubuloids and perfused tubuloid cells-on-*  
474 *a-chip*. Nat Protoc, 2021. **16**(4): p. 2023-2050.
- 475 37. Ichimura, T., et al., *Kidney injury molecule-1 is a phosphatidylserine receptor that confers*  
476 *a phagocytic phenotype on epithelial cells*. J Clin Invest, 2008. **118**(5): p. 1657-1668.
- 477 38. Cong, W., et al., *Implications of the Wnt5a/CaMKII pathway in retinoic acid-induced*  
478 *myogenic tongue abnormalities of developing mice*. Sci Rep, 2014. **4**: p. 6082.
- 479 39. Takai, J., et al., *Heterozygous mutant mice exhibit reduced inflammatory responses and*  
480 *impaired bacterial clearance*. iScience, 2021. **24**(8): p. 102836.

481

## 482 **Acknowledgment**

483 We are deeply grateful to the generous study participants who agreed to donate segments of their  
484 resected kidneys for this research.

485

486 **Funding**

487 This work was supported by various sources, including the Leading Initiative for Excellent Young  
488 Researchers from Ministry of Education, Culture, Sports, Science, and Technology (to Y.M.),  
489 Grant-in-Aid for Research Activity Start-up from Japan Society for the Promotion of Science  
490 (22K20881) (to Y.M.), Innovation Idea Contest from Tokyo Medical and Dental University  
491 (TMDU) (in 2022 to Y.M. and in 2023 to Y.N.), Next Generation Researcher Training Unit from  
492 TMDU (to Y.M.) and Priority Research Areas Grant from TMDU (to Y.M.), Research Grant from  
493 Uehara Memorial Foundation (to Y.M.), Research Grant (Lifestyle-related diseases) from MSD  
494 Life Science Foundation (to Y.M.), Medical Research Grant from Takeda Science Foundation (to  
495 Y.M.), and Academic Support from Bayer Yakuhin, Ltd. (to Y.M.).

496

497 **Data availability statements**

498 The data that support the findings of this study are available from the corresponding author upon  
499 reasonable request. Requests for resources and reagents should be directed to the Lead Contact,  
500 Yutaro Mori (y-mori.kid@tmd.ac.jp).

501

502 **Author contributions**

503 Y.N. and Y.M.: performed the experiments, collected and analyzed data, and prepared the  
504 manuscript.

505 Y.M. and M.M.: established the hRPTECs and S.M. helped with the procedure.

506 T.F., H.K., F.A., K.S., T.M., E.S., and S.U.: supported the data analysis.

507 Y.W., S.Y., and Y.F.: resected the patients' kidneys as standard treatment for malignant diseases.

508 Y.M.: developed experimental strategy, supervised the project, and finalized the manuscript.



509 All authors discussed the results and implications and provided comments on the manuscript.

510

511

512 **Figure Legends**

513 **Figure 1. Formation of highly polarized tubuloid structures from primary human renal**  
514 **proximal tubular epithelial cells (hRPTECs).**

515 (A) Schematic overview of the establishment of tubuloids from hRPTECs isolated from adult  
516 human kidney.

517 (B) Image of the human resected kidney utilized during the establishment of hRPTECs.

518 (C) Representative image showing hRPTECs. Scale bars: 50  $\mu\text{m}$ .

519 (D) Two-week protocol for generating tubuloids from 2D-cultured hRPTECs.

520 (E) Representative image demonstrating the seeding of hRPTECs on an ultralow attachment plate.  
521 Scale bars: 25  $\mu\text{m}$ .

522 (F) Representative images of tubuloids at different magnifications ( $\times 10$ ,  $\times 40$ ). Scale bars: 100  $\mu\text{m}$ ,  
523 25  $\mu\text{m}$ .

524 (G) Representative image of tubuloids at  $\times 40$  magnification, showing multiple layers along the Z  
525 axis. Scale bars: 25  $\mu\text{m}$ .

526 (H) Immunostaining of makers for renal proximal tubular epithelial cells (LRP2/Megalin and  
527 LTL). Scale bars: 25  $\mu\text{m}$ .

528

529

530 **Figure 2. Effects of cisplatin treatment on tubuloid structure, DNA damage response,**  
531 **differentiation loss, cell death, and epithelial-mesenchymal transition.**

532 (A) Schematic representation of the pathway by which cisplatin induces DNA damage in proximal  
533 tubular epithelial cells.

534 (B) Representative images of tubuloids exposed to cisplatin (0.2, 2.0, 20.0  $\mu\text{g/mL}$ ) or control.

535 (C) Immunostaining of the DNA damage marker,  $\gamma$ H2AX, in tubuloids exposed to cisplatin (0.2,  
536 2.0, 20.0  $\mu\text{g}/\text{mL}$ ) or control. Scale bars: 100  $\mu\text{m}$ . (D) Immunostaining of a differentiation marker  
537 for epithelial cells, LRP2/Megalin in tubuloids exposed to cisplatin (20.0  $\mu\text{g}/\text{mL}$ ) or control. Scale  
538 bars: 25  $\mu\text{m}$ .

539 (E) Immunostaining of a differentiation marker for epithelial cells,  $\text{Na}^+/\text{K}^+$ -ATPase in tubuloids  
540 exposed to cisplatin (20.0  $\mu\text{g}/\text{mL}$ ) or control. Scale bars: 25  $\mu\text{m}$ .

541 (F) Immunostaining of an epithelial injury marker, Kidney Injury Molecule-1 (KIM-1) in tubuloids  
542 exposed to cisplatin (20.0  $\mu\text{g}/\text{mL}$ ) or control. Scale bars: 25  $\mu\text{m}$ .

543 (G) Western blotting analysis of KIM-1 in tubuloids exposed to cisplatin (0.2, 2.0  $\mu\text{g}/\text{mL}$ ) or  
544 control.

545 (H) Immunostaining of an apoptosis marker, Cleaved Caspase-3, in tubuloids exposed to cisplatin  
546 (20.0  $\mu\text{g}/\text{mL}$ ) or control. Scale bars: 25  $\mu\text{m}$ .

547 (I) Immunostaining of intermediate filament, Vimentin, in tubuloids exposed to cisplatin (20.0  
548  $\mu\text{g}/\text{mL}$ ) or control. Scale bars: 100  $\mu\text{m}$ .

549 (J) Western blotting analysis of Vimentin in tubuloids exposed to cisplatin (0.2, 2.0  $\mu\text{g}/\text{mL}$ ) or  
550 control.

551  
552 **Figure 3. Tubuloids exhibit cellular senescence and release inflammatory cytokines following**  
553 **repeated cisplatin treatment.**

554 (A) Experimental design for repeated cisplatin injury.

555 (B) Western blotting analysis of p16 in tubuloids exposed to cisplatin (0.2, 2.0  $\mu\text{g}/\text{mL}$ ) repeatedly  
556 or control.

557 (C) Quantification of relative protein levels of p16 / ERK1/2. \* $P = 0.0233$  ( $n = 4$ ).

558 (D) Immunostaining of p16 in tubuloids exposed to cisplatin (2.0 µg/mL) repeatedly or control.

559 Scale bars: 100 µm.

560 (E) Immunostaining of an inflammatory cytokine, IL-1β, in tubuloids exposed to cisplatin (2.0

561 µg/mL) repeatedly or control. Scale bars: 100 µm.

562 (F) Quantitative PCR of IL-1β and IL-6 in tubuloids exposed to cisplatin (0.2, 2.0 µg/mL)

563 repeatedly or control. Statistical analysis was applied to the delta-delta Ct value, not fold increase.

564 \**P* = 0.0167 (*n* = 3), \*\**P* = 0.0011 (*n* = 3).

565

566 **Figure 4. Secretion released from cisplatin-treated tubuloids strongly promotes fibrosis *in***

567 *vitro*.

568 (A) Experimental design for fibrosis bioassay.

569 (B) A representative image of Mouse Primary Kidney Fibroblasts (MPKFs). Scale bar: 25 µm.

570 (C) Representative images of fibrosis bioassay on MPKFs cultured with Conditioned Media (CM)

571 harvested from tubuloids exposed to cisplatin (0.2, 2.0 µg/mL) or control, or directly with

572 cisplatin-containing media. Scale bars: 100 µm.


573 (D) Quantification of the αSMA-positive area in MPKFs cultured with CM or directly with

574 cisplatin-containing media measured by Image J. \*\**P* = 0.0021, \*\*\**P* = 0.0001, \*\*\*\**P* < 0.0001.

575 (*n* = 8–10 each condition)

576

577



## Graphical Abstract






Figure 1

579

580



**Figure 2**



**Figure 3**

582

583






Figure 4